04, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
For non-standard doses, the free reconstitution calculator works out the exact units for any vial size, water volume, and target dose combination
These tests screen for substances of abuse, not prescription medications like Ozempic, Wegovy, Mounjaro, or Zepbound
Liraglutide is currently under investigation for its potential effects on obesity-related conditions such as polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and others
~ clearance rate
Antidepressant-like effect of genipin in mice